Rubicon Research: Navigating Market Waves with Innovative Pharmaceutical Offerings

Rubicon Research's IPO was 84% subscribed by the second day. Retail and non-institutional investor participation is high. The IPO aims to raise Rs 1,377.5 crore, with Rs 310 crore for debt repayment and growth. The company continues expanding its R&D and manufacturing capabilities.

Rubicon Research has gained significant traction with its initial public offering (IPO), reaching 84% subscription by the second day of bidding.

Retail individual investors have shown considerable interest, with their quota being fully subscribed 2.48 times. Amidst this financial maneuvering, the company aims to mobilize Rs 1,377.5 crore.

The raised funds will aid in debt repayment and fuel growth through strategic initiatives. Rubicon Research emphasizes strong R&D and has recently expanded with acquisitions like Alkem Laboratories' facility.

(With inputs from agencies.)